Gemini Therapeutics, Inc. Common Stock (GMTX)

Etorro trading 970x250

About Gemini Therapeutics, Inc. Common Stock

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts. Address: 300 One Kendall Square, Cambridge, MA, United States, 02139

Gemini Therapeutics, Inc. Common Stock News and around…

Latest news about Gemini Therapeutics, Inc. Common Stock (GMTX) common stock and company :

Adding Up The Components: Russell 2000 Could Rise 30%
11 Jan, 2022 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Gemini Therapeutics Provides GEM103 Program Update
10 Jan, 2022 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s clinical development program.

46 Biggest Movers From Yesterday
16 Dec, 2021 FinancialContent

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. ...

Mid-Afternoon Market Update: Dow Surges Over 100 Points After Federal Reserve's Policy Update
15 Dec, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded up 0.35% to 35,669.27 while the NASDAQ rose 0.44% to 15,304.76. The S&P also ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
15 Dec, 2021 FinancialContent

Gainers Biofrontera (NASDAQ:BFRI) stock moved upwards by 28.18% to $7.05 during Wednesday's regular session. The ...

Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside
15 Dec, 2021 FinancialContent

H.C. Wainwrightinitiated coverageofGemini Therapeutics Inc(NASDAQ: GMTX) with a Buy rating and $20 price ...

Mid-Day Market Update: REV Group Drops After Q4 Results; CMC Materials Shares Climb
15 Dec, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded down 0.30% to 35,436.90 while the NASDAQ fell 0.57% to 15,150.48. The S&P also ...

36 Stocks Moving In Wednesday's Mid-Day Session
15 Dec, 2021 FinancialContent

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services ...

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
15 Dec, 2021 FinancialContent

Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:OGS) from Neutral to Buy. For the third ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
15 Dec, 2021 FinancialContent

Gainers Gemini Therapeutics (NASDAQ:GMTX) shares moved upwards by 32.92% to $3.23 during Wednesday's pre-market ...

Implied UWM Analyst Target Price: $70
09 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Russell2000 ETF (UWM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $69.93 per unit.

What Type Of Shareholders Own The Most Number of Gemini Therapeutics, Inc. (NASDAQ:GMTX) Shares?
08 Dec, 2021 Yahoo! Finance

If you want to know who really controls Gemini Therapeutics, Inc. ( NASDAQ:GMTX ), then you'll have to look at the...

Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
15 Nov, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial results for the third quarter ended September 30, 2021 and provided a business update.

Gemini Therapeutics Announces Poster Presentation at AAO 2021
12 Nov, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, will present a poster at the 2021 Annual Meeting of the American Academy of Ophthalmology (AAO), which is being held virtually and in-person at the Ernest N. Morial Convention Center, New Orleans, LA on November 12 – 15, 2021.

Gemini Therapeutics to Participate in Upcoming Investor Conferences
11 Nov, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:

Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
19 Oct, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced Chief Medical Officer, Samuel Barone, M.D., will present virtually at the 2nd Annual Dry AMD Therapeutic Development Summit: Uncovering the Largest Untapped Eyecare Market on October 20, 2021, at 1:45 PM ET during “Spotlight on GEM103 – Restoring Physiologic Complement Activity with Complement Factor H (CFH) for GA.” Dr. Barone will be presenting previously released data from Gemini’s Phase 2a study of GEM103.

Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
14 Oct, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the grant of inducement awards under Gemini’s 2021 Inducement Plan to two new employees of options to purchase an aggregate of 217,000 shares of Gemini’s common stock. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Gemini’s Compensation Committee and made as a material inducement to each employee’s entry into employment with Gemini.

Analysts Expect 14% Gains Ahead For ITOT
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

Gemini Axes Chief Scientific Officer, 20% Of Staff To Focus On Geographic Atrophy Candidate
05 Oct, 2021 FinancialContent

Gemini Therapeutics Inc(NASDAQ: GMTX) announced a corporate restructuring, including several executive officer transitions, ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
05 Oct, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced a corporate restructuring, including several executive officer transitions, to prioritize assets and focus on initiating and executing GEM103’s resource-intensive pivotal trial in geographic atrophy (GA).

Lightstone Ventures Raises $375 Million Fund
14 Sep, 2021 Yahoo! Finance

Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacso

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
10 Sep, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced one oral presentation and the presentation of three posters at the 13th International Conference on Complement Therapeutics held in Ioannina, Greece from September 8-13, 2021.

12 Health Care Stocks Moving In Thursday's After-Market Session
09 Sep, 2021 FinancialContent

Gainers IVERIC bio (NASDAQ:ISEE) shares moved upwards by 31.76% to $11.45 during Thursday's after-market session. Trading volume for ...

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
09 Sep, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing Phase 2a study at EURETINA 2021 Virtual held from September 9-12, 2021. The ReGAtta study is an open-label, single-arm dose escalation study of GEM103 in genetically-defined patients with geographic atrophy (GA) secondary to dry AMD.

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
09 Sep, 2021 Yahoo! Finance

CAMBRIDGE, Mass., September 09, 2021--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing Phase 2a study at EURETINA 2021

Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7 AM ET on Monday, September 13, 2021.

55 Biggest Movers From Yesterday
01 Sep, 2021 FinancialContent

Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. ...

12 Health Care Stocks Moving In Monday's After-Market Session
31 Aug, 2021 FinancialContent

Gainers Sonnet BioTherapeutics (NASDAQ:SONN) stock moved upwards by 20.91% to $0.68 during Monday's after-market session. Today's ...

Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
30 Aug, 2021 FinancialContent

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Chief Executive Officer, Jason Meyenburg, and Chief Medical Officer, Samuel Barone, M.D., presented in panel discussions at the Clinical Trials at the Summit on August 28, 2021. As part of the panel discussions, which included: Concept to Concrete: Turning Ideas into Action and Clinical Trials Addressing Dry AMD, management discussed some of the previously released initial data from its ongoing Phase 2a ReGAtta study of GEM103 in patients with geographic atrophy (GA) secondary to dry AMD as of May 2021.

Gemini Therapeutics, Inc. Common Stock (GMTX) is a NASDAQ Common Stock listed in , ,

970x250